Index
NDX, RUI
Market Cap
21.43B
Enterprise Value
20.84B
Income
2.72B
Sales
5.01B
Book/sh
26.92
Cash/sh
26.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
2500
IPO
May 28, 2004
P/E
8.08
Forward P/E
17.85
PEG
0.26
P/S
4.27
P/B
5.94
P/C
5.97
P/FCF
28.49
EV/EBITDA
20.17
EV/Sales
4.16
Quick Ratio
2.43
Current Ratio
2.48
Debt/Eq
0.83
LT Debt/Eq
0.64
Option/Short
Yes / Yes
EPS (ttm)
19.80
EPS next Y
8.96
EPS next Q
1.72
EPS this Y
690.54%
EPS next Y
-51.33%
EPS next 5Y
68.70%
EPS past 3/5Y
- -
Sales past 3/5Y
52.98% 49.77%
EPS Y/Y TTM
6459.20%
Sales Y/Y TTM
56.17%
EPS Q/Q
754.21%
Sales Q/Q
16.74%
Insider Own
0.32%
Insider Trans
-0.48%
Inst Own
100.41%
Inst Trans
0.07%
ROA
42.41%
ROE
141.97%
ROIC
46.01%
Gross Margin
77.28%
Oper. Margin
19.50%
Profit Margin
54.34%
SMA20
-11.20%
SMA50
-25.63%
SMA200
-41.55%
Trades
Shs Outstand
133.88M
Shs Float
133.51M
52W High
479.79 -66.65%
52W Low
149.18 7.25%
Volatility
5.46% 5.36%
ATR (14)
9.65
RSI (14)
32.67
Beta
0.45
Rel Volume
0.00
Avg Volume
2.05M
Volume
276
Perf Week
5.51%
Perf Month
-31.42%
Perf Quarter
-34.05%
Perf Half Y
-45.64%
Perf YTD
-59.77%
Perf Year
-65.26%
Perf 3Y
-2.28%
Perf 5Y
-7.38%
Perf 10Y
245.10%
Prev Close
159.73
Price
159.99
Change %
0.16%
Analysts 15 incl. previous ratings
Rating Distribution 10 Buy · 5 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Nov 02, 2026 Downgrade T Truist
Buy → Hold $225 +40.6% Oct 30, 2026 Downgrade R Raymond James
Strong Buy → Outperform $315 +96.9% Oct 30, 2026 Downgrade B Bernstein
Outperform → Mkt Perform $199 +24.4% Oct 29, 2026 Downgrade S Stifel
Buy → Hold $225 +40.6% Oct 15, 2026 Resumed U UBS
Buy $354 +121.3% Aug 19, 2026 Initiated B BMO Capital Markets
Outperform $318 +98.8% Aug 03, 2026 Upgrade R Raymond James
Outperform → Strong Buy $420 +162.5% May 19, 2026 Initiated C Citigroup
Buy $380 +137.5% Mar 16, 2026 Downgrade J Jefferies
Buy → Hold $330 +106.3% Jan 28, 2026 Resumed B Barclays
Overweight $527 +229.4% Jan 07, 2026 Resumed O Oppenheimer
Outperform $500 +212.5% Aug 04, 2025 Upgrade W Wolfe Research
Underperform → Peer Perform Aug 04, 2025 Upgrade O Oppenheimer
Perform → Outperform $490 +206.3% Jul 30, 2025 Resumed R Raymond James
Outperform $370 +131.3% Jul 21, 2025 Initiated T Truist
Buy $385 +140.6% Mar 31, 2025 Initiated R Redburn Atlantic
Buy $353 +120.6% Mar 24, 2025 Upgrade J JP Morgan
Neutral → Overweight $280 → $328 +105.0% Nov 12, 2024 Downgrade W Wolfe Research
Peer Perform → Underperform Oct 16, 2024 Initiated B Scotiabank
Sector Outperform Aug 16, 2024 Upgrade G Goldman
Neutral → Buy $198 → $370 +131.3%
Show Previous Ratings
Nov-10-26 09:00AM
Nov-09-26 09:50AM
Nov-06-26 08:13AM
Nov-04-26 04:15PM
02:47PM
07:00AM
Loading…
07:00AM
Nov-03-26 08:30AM
Nov-02-26 09:00AM
05:36AM
Oct-29-26 02:26PM
10:07AM
08:14AM
08:00AM
Oct-23-26 03:45AM
Oct-21-26 09:53AM
10:19AM
Loading…
Oct-19-26 10:19AM
Oct-18-26 11:15PM
Oct-16-26 10:44AM
06:50AM
06:33AM
Oct-15-26 08:00AM
Oct-12-26 05:01PM
Oct-09-26 11:36AM
Sep-29-26 09:00AM
Sep-24-26 08:36PM
Sep-22-26 01:39PM
Sep-15-26 11:18AM
Sep-02-26 08:00AM
Aug-31-26 08:48AM
Aug-30-26 08:23AM
05:18PM
Loading…
Aug-28-26 05:18PM
08:54AM
06:58AM
Aug-26-26 11:13AM
Aug-24-26 03:01PM
08:33AM
Aug-20-26 02:21PM
Aug-11-26 06:21AM
Aug-03-26 09:49AM
Jul-31-26 03:29PM
Jul-30-26 05:04PM
12:12PM
08:16AM
08:00AM
Jul-23-26 11:00AM
Jul-16-26 09:06AM
08:00AM
Jul-15-26 03:30AM
Jul-13-26 09:12AM
Jul-10-26 08:14AM
07:35AM
Jul-09-26 10:38AM
(The Wall Street Journal)
07:38AM
07:14AM
Jul-08-26 08:48AM
Jun-25-26 09:00AM
Jun-12-26 09:00AM
Jun-04-26 06:42AM
Jun-03-26 04:45PM
May-28-26 04:27PM
May-20-26 03:29PM
May-19-26 09:34AM
09:33AM
08:30AM
May-12-26 02:30AM
May-07-26 08:00AM
May-04-26 08:30AM
Apr-30-26 09:15AM
(Investor's Business Daily)
08:09AM
08:00AM
Apr-16-26 08:00AM
Apr-07-26 10:00AM
09:49AM
Mar-30-26 01:00PM
Mar-24-26 07:30AM
Mar-16-26 09:37AM
Mar-10-26 02:49PM
08:00AM
Mar-06-26 07:19AM
(Pharmaceutical Technology)
05:13AM
Mar-05-26 01:35PM
Mar-04-26 06:57AM
Mar-02-26 11:39PM
Mar-01-26 01:33AM
Feb-24-26 11:43AM
Feb-23-26 10:00AM
Feb-20-26 04:08AM
Feb-19-26 12:01AM
Feb-17-26 12:09PM
(Pharmaceutical Technology)
+5.79%
Feb-14-26 01:21AM
Feb-13-26 04:30PM
(Morningstar Research)
+5.79%
10:19AM
Feb-12-26 04:06PM
12:23PM
10:00AM
09:10AM
08:22AM
(Associated Press Finance)
08:00AM
Feb-11-26 12:57PM
Feb-10-26 10:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PYOTT DAVID E I Director Nov 10 '26 Option Exercise 71.99 3,780 272,122 5,362 Nov 12 04:07 PM Sigal Charles Elliott Director Nov 10 '26 Buy 152.25 1,600 243,600 3,600 Nov 12 04:05 PM SCHULMAN AMY W Director Nov 09 '26 Buy 156.82 1,910 299,526 25,959 Nov 12 04:01 PM SUPRAN BRYAN EVP, CLO and Secretary Oct 02 '26 Sale 226.88 1,758 398,855 12,807 Oct 06 04:12 PM SUPRAN BRYAN Officer Oct 02 '26 Proposed Sale 226.88 1,758 398,862 Oct 02 03:45 PM PYOTT DAVID E I Director Jun 01 '26 Option Exercise 0.00 3,830 0 5,412 Jun 03 04:25 PM PYOTT DAVID E I Director Jun 01 '26 Sale 299.18 3,830 1,145,853 1,582 Jun 03 04:25 PM PYOTT DAVID E I Director Jun 01 '26 Proposed Sale 299.51 3,830 1,147,123 Jun 01 04:25 PM SCHULMAN AMY W Director May 13 '26 Option Exercise 70.20 11,250 789,750 23,211 May 14 04:17 PM McLaughlin Melissa Chief Human Resources Officer Apr 06 '26 Sale 330.42 2,286 755,329 9,443 Apr 07 04:21 PM McLaughlin Melissa Chief Human Resources Officer Apr 02 '26 Sale 319.59 1,624 519,014 11,729 Apr 07 04:21 PM McLaughlin Melissa Officer Apr 06 '26 Proposed Sale 320.10 2,286 731,749 Apr 06 04:05 PM Garg Pushkal EVP Chief R&D Mar 05 '26 Sale 323.96 2,404 778,812 18,693 Mar 06 04:13 PM Garg Pushkal EVP Chief R&D Mar 04 '26 Sale 323.08 2,309 745,984 21,097 Mar 06 04:13 PM Greenstreet Yvonne Chief Executive Officer Mar 04 '26 Sale 323.08 2,933 947,581 95,695 Mar 06 04:13 PM Poulton Jeffrey V. EVP, Chief Financial Officer Mar 04 '26 Sale 323.08 2,468 797,351 61,805 Mar 06 04:12 PM Tanguler Tolga EVP, Chief Commercial Officer Mar 04 '26 Sale 323.08 2,309 745,984 34,297 Mar 06 04:12 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Mar 05 '26 Sale 323.98 658 213,177 20,569 Mar 06 04:11 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Mar 04 '26 Sale 323.08 633 204,508 21,227 Mar 06 04:11 PM Fitzgerald Kevin Joseph Officer Mar 05 '26 Proposed Sale 323.69 658 212,988 Mar 05 04:04 PM Garg Pushkal Officer Mar 05 '26 Proposed Sale 323.69 2,404 778,151 Mar 05 04:03 PM Poulton Jeffrey V. EVP, Chief Financial Officer Mar 02 '26 Sale 327.65 2,206 722,801 64,273 Mar 04 07:31 PM Garg Pushkal EVP Chief R&D Mar 03 '26 Sale 319.74 1,775 567,546 23,406 Mar 04 07:31 PM Garg Pushkal EVP Chief R&D Mar 02 '26 Sale 327.66 1,717 562,585 25,181 Mar 04 07:31 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Mar 03 '26 Sale 319.73 1,652 528,189 21,860 Mar 04 07:30 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Mar 02 '26 Sale 327.65 1,598 523,584 23,512 Mar 04 07:30 PM Tanguler Tolga EVP, Chief Commercial Officer Mar 02 '26 Sale 327.65 1,598 523,584 36,606 Mar 04 07:30 PM Greenstreet Yvonne Chief Executive Officer Mar 02 '26 Sale 327.65 6,799 2,227,698 98,628 Mar 04 07:29 PM Fitzgerald Kevin Joseph Officer Mar 03 '26 Proposed Sale 321.37 1,652 530,903 Mar 03 04:49 PM Garg Pushkal Officer Mar 03 '26 Proposed Sale 321.37 1,775 570,432 Mar 03 04:11 PM Greenstreet Yvonne Chief Executive Officer Feb 27 '26 Option Exercise 0.00 5,921 0 91,583 Mar 02 04:10 PM Poulton Jeffrey V. EVP, Chief Financial Officer Feb 27 '26 Option Exercise 0.00 1,908 0 61,710 Mar 02 04:09 PM Tanguler Tolga EVP, Chief Commercial Officer Feb 27 '26 Option Exercise 0.00 1,666 0 33,435 Mar 02 04:09 PM Garg Pushkal EVP Chief R&D Feb 27 '26 Option Exercise 0.00 1,908 0 26,756 Mar 02 04:08 PM Garg Pushkal EVP Chief R&D Feb 27 '26 Sale 331.34 4,627 1,533,100 22,129 Mar 02 04:08 PM Garg Pushkal Officer Feb 27 '26 Proposed Sale 331.34 4,627 1,533,107 Feb 27 04:05 PM Garg Pushkal EVP Chief R&D Feb 13 '26 Sale 310.08 2,242 695,201 24,848 Feb 17 07:28 PM Greenstreet Yvonne Chief Executive Officer Feb 13 '26 Sale 310.08 6,958 2,157,542 85,662 Feb 17 07:27 PM Tanguler Tolga EVP, Chief Commercial Officer Feb 13 '26 Sale 310.08 1,959 607,448 31,769 Feb 17 07:27 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Feb 17 '26 Sale 331.96 2,041 677,532 21,264 Feb 17 07:26 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Feb 13 '26 Sale 310.08 1,959 607,448 23,305 Feb 17 07:26 PM Poulton Jeffrey V. EVP, Chief Financial Officer Feb 13 '26 Sale 310.08 2,242 695,201 59,802 Feb 17 07:26 PM Fitzgerald Kevin Joseph Officer Feb 17 '26 Proposed Sale 331.96 2,041 677,532 Feb 17 04:10 PM Garg Pushkal EVP Chief R&D Jan 12 '26 Sale 362.87 1,510 547,929 22,511 Jan 14 04:23 PM Greenstreet Yvonne Chief Executive Officer Jan 12 '26 Sale 362.86 9,577 3,475,157 78,411 Jan 14 04:23 PM Poulton Jeffrey V. EVP, Chief Financial Officer Jan 12 '26 Sale 362.87 2,780 1,008,766 57,465 Jan 14 04:22 PM Tanguler Tolga EVP, Chief Commercial Officer Jan 12 '26 Sale 362.87 1,510 547,927 29,728 Jan 14 04:22 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Jan 13 '26 Sale 370.33 2,290 848,065 21,264 Jan 14 04:21 PM Fitzgerald Kevin Joseph CSO & EVP, Head of Research Jan 12 '26 Sale 362.87 1,510 547,927 23,554 Jan 14 04:21 PM Fitzgerald Kevin Joseph Officer Jan 13 '26 Proposed Sale 369.10 2,290 845,239 Jan 13 04:32 PM Greenstreet Yvonne Chief Executive Officer Nov 26 '25 Option Exercise 106.40 4,697 499,756 70,106 Dec 01 04:10 PM
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.
M.D. Dr. Yvonne L. Greenstreet M.B.A.
Co-Founder Dr. Phillip A. Sharp Ph.D.
CFO & Executive VP Mr. Jeffrey V. Poulton M.B.A.
Chief Legal Officer Mr. Bryan Andrew Supran J.D.
Executive VP & Chief Research & Development Officer Dr. Pushkal P. Garg M.D.